Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are set to rally after the FDA granted emergency use authorisation (EUA) for the firm’s COVID-19 treatment, which was given to President Donald Trump after he contracted the coronavirus in October.
The company had submitted an emergency use application after the drug known as REGN-COV2 after preclinical studies showed that the drug reduced the virus levels and associated damage in the lungs of non-human primates.
Regeneron’s therapy belongs to a class of drugs known as monoclonal antibodies that act as immune cells and can prevent infections.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
FDA Commissioner, Stephen M. Hahn, said: “The FDA remains committed to advancing the nation’s public health during this unprecedented pandemic. Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,”
Regeneron’s treatment is the second coronavirus treatment authorised by the FDA this month following the approval of Eli Lilly’s antibody treatment called bamlanivimab for use in people who have just been infected with the coronavirus and are yet to develop a severe form of the disease.
Regeneron share price
Regeneron shares are up 38% this year, although they are down 9.9% this month.
People who read this also read:
